Table 1 Clinical and laboratory characteristics of 270 Mayo Clinic patients and 232 University of Florence patients with essential thrombocythemia (ET) (total n = 502).
Variables | Mayo Clinic (n = 270) | Florence (n = 232) |
|---|---|---|
Age in years; median (range) | 57 (18–92) | 54 (13–85) |
Males; n (%) | 108 (40) | 96 (41) |
Hemoglobin, g/dl; median (range) “N” evaluable = 382 (92%) | 13.7 (6.9–17.9)a | 14.1 (12–17.0)a |
Platelets, ×109/L; median (range) “N” evaluable = 407 (98%) | 844 (451–3330) | 739 (451–2000) |
Platelets > 1000 × 109/l; n (%) “N” evaluable = 407 (98%) | 82 (31) | 33 (16) |
Leukocytes, ×109/L; median (range) “N” evaluable = 399 (96%) | 8.7 (2.7–70.7) | 8.5 (3.8–26) |
Leukocytes ≥ 11 × 109/l; n (%) “N” evaluable = 399 (96%) | 64 (25) | 36 (19) |
Palpable splenomegaly “N” evaluable = 412 (99%) | 48 (18) | 45 (21) |
Karyotype “N” evaluable = 345 (83%) | ||
Abnormal; n (%) | 20 (9) | 15 (10) |
Fibrotic progression; n (%) | 44 (16) | 76 (33)b |
Leukemic transformations; n (%) | 12 (4) | 15 (6.5) |
Follow up in years; median (range) | 9.9 (0–34.6) | 12.9 (1–36.3) |
Deaths; n (%) | 104 (39) | 87 (38) |
Mutationsc | ||
JAK2 mutated; n (%) | 146 (54) | 129 (56) |
CALR mutated; n (%) | 79 (29) | 59 (25) |
TET2 mutated; n (%) | 25 (9) | 28 (11) |
ASXL1 mutated; n (%) | 18 (7) | 47 (20)b |
DNMT3A mutated; n (%) | 19 (7) | 14 (7) |
SF3B1 mutated; n (%) | 14 (5) | 12 (5) |
SH2B3 mutated; n (%) | 3 (1) | 6 (3) |
SRSF2 mutated; n (%) | 6 (2) | 6 (3) |
MPL mutated; n (%) | 11 (4) | 17 (7) |
KIT mutated; n (%) | 5 (2) | 2 (1) |
IDH2 mutated; n (%) | 4 (1) | 2 (1) |
TP53 mutated; n (%) | 5 (2) | 9 (4) |
U2AF1 mutated; n (%) | 3 (1) | 6 (2.5) |
RUNX1 mutated; n (%) | 4 (1) | 5 (2) |
EZH2 mutated; n (%) | 5 (2) | 9 (4) |
CBL mutated; n (%) | 3 (1) | 3 (2) |
